Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 175.77B +37.4% |
| Revenue (ttm) | 33.34B +9.1% |
| Net Income | 7.65B +32.1% |
| EPS | 14.09 +31.6% |
| Shares Out | n/a |
| PE Ratio | 22.97 |
| Forward PE | 15.99 |
| Dividend | 8.50 (2.60%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 285 |
| Open | 332.25 |
| Previous Close | 329.90 |
| Day's Range | 326.25 - 332.85 |
| 52-Week Range | 230.00 - 383.05 |
| Beta | 0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Amgen Transcript: Wells Fargo 21st Annual Healthcare Conference
Quarterly revenues exceeded $10 billion, driven by strong growth across six key product areas and robust pipeline progress. Landmark clinical results for IMDELLTRA and TEZSPIRE, expanding biosimilar portfolio, and strategic focus on productivity and disciplined investment support a positive long-term outlook.
HSBC downgrades Amgen to Hold on fair value after re-rating
HSBC analyst Morten Herholdt last night downgraded Amgen (AMGN) to Hold from Buy with a price target of $425, down from $445. After re-rating on Amgen’s strong execution and positive…
Amgen downgraded to Hold from Buy at HSBC
HSBC downgraded Amgen (AMGN) to Hold from Buy with a price target of $425, down from $445.
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m.
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Amgen (AMGN) shares sold off after Novartis (NVS) failed to meet its primary endpoint in phase-3 trials. Diane King Hall offers more insight into the volatile moves in the healthcare space.
Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint
Amgen (AMGN) announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningf...
AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab
Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s (AMGN) tarlatamab demonstrated a statistically significant and highly clinica...
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Respo...
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market
AI stocks rise despite the market's inflation worries, but Amgen falls following Swiss drugmaker Novartis' disappointing trial data.
Why Amgen Stock Is Dropping After Swiss Rival's Trial Setback
Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.
Amgen downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Amgen (AMGN) to Market Perform from Outperform with an unchanged price target of $450. The firm cites valuation for the downgrade, saying Amgen’s commercial execution “is now…
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Novartis pelacarsen miss ‘not great on the margin for’ Amgen, says UBS
After Novartis (NVS) announced pelacarsen missed its primary endpoint of reducing cardiovascular events in the Phase 3 HORIZON study, UBS called the news “not great on the margin for” Amgen…
Amgen price target raised to $435 from $400 at Wells Fargo
Wells Fargo raised the firm’s price target on Amgen (AMGN) to $435 from $400 and keeps an Equal Weight rating on the shares. Given where the stock currently trades, the…
Amgen price target raised to $435 from $400 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Amgen (AMGN) to $435 from $400 and keeps an Equal Weight rating on the shares. The firm says its…
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.
UK regulator suspends Amgen's Tavneos for new patients over unreliable data
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
Amgen Repatha reduces risk of death in high-risk adults for first heart attack
Amgen (AMGN) announced new findings showing Repatha reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein…
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Gl...
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements
Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant...
AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial Success
Shares in pharmaceuticals giant AstraZeneca ($AZN) and peer Amgen ($AMGN) both dropped in pre-market trading despite hailing successful trial results for a new esophagus drug. AZN said that its asthma...